# CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin

> **NCT03002805** · PHASE1 · UNKNOWN · sponsor: **CBA Research** · enrollment: 46 (estimated)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** CBT-1®

## Key facts

- **NCT ID:** NCT03002805
- **Lead sponsor:** CBA Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-29
- **Primary completion:** 2020-09
- **Final completion:** 2020-09
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2019-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03002805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03002805, "CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03002805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*